

| Drug common name | BELVARAFENIB |
| INN | belvarafenib |
| Description | Belvarafenib (developed by Hanmi Pharmaceuticals and Genentech) is a small molecule RAF dimer (type II) inhibitor which shows anti-tumor clinical activity in cancer patients with BRAFV600E- and NRAS- mutations.
|
| Classification | Small molecule |
| Drug class | rapidly accelerated fibrosarcoma (RAF) kinase inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12 |
| PDB | — |
| CAS-ID | 1446113-23-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3977543 |
| ChEBI ID | — |
| PubChem CID | 89655386 |
| DrugBank | — |
| UNII ID | 31M3WLJ3KG (ChemIDplus, GSRS) |
